Outcome of Diffuse Large B-Cell Lymphoma with First-line Chemotherapy
Open Access
- 6 May 2021
- journal article
- Published by Haematology Society of Bangladesh in Haematology Journal of Bangladesh
- Vol. 5 (01), 03-09
- https://doi.org/10.37545/haematoljbd202156
Abstract
Background: Diffuse Large B-Cell Lymphoma (DLBCL), most common Non-Hodgkin Lymphoma (NHL) variety, is an aggressive, fast-growing form comprising up to 40% of all cases globally. Objective: To observe the treatment outcome of different subtypes of Diffuse Large B-Cell Lymphoma (DLBCL) after first-line chemotherapy and also the association with IHC, presenting age, sex, and IPI score with outcome. Methodology: This is a retrospective data analysis included all DLBCL patients registered in the department of Haematology of National Institute of Cancer Research and Hospital (NICRH) between July 2016 to June 2019. Results: Total 188 cases were included in this study and mean age was 48 years with a Standard deviation of 15 years with Male (69.1%) predominance. We divide the cases into three different entities of DLBCL [Germinal Centre B-cell like (GCB), Non-GCB and others (NOS) among them Non-GCB variety was the prevalent (47.3%) one. After first line chemotherapy 52.1% complete remission with 7% death was observed in overall outcome. There was no significant difference in outcome among different types of DLBCL after chemotherapy based on Han’s algorithm. Rituximab with CHOP has significantly better outcome than CHOP alone arm (p: 0.021). Conclusion: This limited database study of NICRH will help to ascertain the outcome of DLBCL after first-line chemotherapy in Bangladesh.Keywords
This publication has 11 references indexed in Scilit:
- Diffuse large B-cell lymphoma: An institutional analysisSouth Asian Journal of Cancer, 2018
- Diffuse large B-cell lymphoma: 10�years' real-world clinical experience with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisoloneOncology Letters, 2018
- The 2016 revision of the World Health Organization classification of lymphoid neoplasmsBlood, 2016
- Histopathological pattern of lymphomas and clinical presentation and outcomes of diffuse large B cell lymphoma: A multicenter registry based study from IndiaIndian Journal of Medical and Paediatric Oncology, 2013
- B cell non-Hodgkin’s lymphoma: experience from a tertiary care cancer centerAnnals of Hematology, 2012
- The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangementHaematologica, 2007
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'AdulteJournal of Clinical Oncology, 2005
- Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarrayBlood, 2004
- Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's LymphomaThe New England Journal of Medicine, 1993